Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the specification:

Listing of Claims

Claims 1 -10. (**Cancelled**)

Claim 11. (**Currently Amended**) A compound of formula Ia or Ib



Ia



Ib

or its pharmaceutically acceptable salts ~~in free or salt form~~, where

Ar is phenyl optionally substituted by one or more substituents selected from halogen, C_1-C_8-alkyl, cyano or nitro;

X^1 is -S-, -S(=O)- or $-S(=O)_2$-;

X^2 is ~~$-C(=O)-$, -O-, $-CH_2-$~~, -S-, -S(=O)- or $-S(=O)_2$-;

m is 1, 2, 3 or 4;

R^1 is hydrogen or C_1-C_8-alkyl optionally substituted by hydroxy, C_1-C_8-alkoxy, acyloxy, halogen, carboxy, C_1-C_8-alkoxycarbonyl, $-N(R^4)R^5$, $-CON(R^6)R^7$ or by a monovalent cyclic organic group having 3 to 15 atoms in the ring system;

Q has the formula

where R^a is C_1-C_8-alkylene,

or Q is $-C(R^b)(R^c)$- where R^b and R^c are independently C_1-C_8-alkyl

or R^b and R^c together form a C_3-C_{10}-cycloalkyl;

Y is oxygen or sulfur;

R^2 is hydrogen, C_1-C_8-alkyl or C_3-C_{10}-cycloalkyl and R^3 is C_1-C_8-alkyl substituted by phenyl, phenoxy, acyloxy or naphthyl, or R^3 is C_3-C_{10}-cycloalkyl optionally having a benzo group fused thereto, a heterocyclic group having 5 to 11 ring atoms of which 1 to 4 are hetero atoms, phenyl

or naphthyl, said phenyl, phenoxy or naphthyl groups being optionally substituted by one or more substituents selected from halogen, cyano, hydroxy, acyl, nitro, $-SO_2NH_2$, C_1-C_8-alkyl optionally substituted by C_1-C_8-alkoxy, C_1-C_8-haloalkyl, C_1-C_8-alkoxy, C_1-C_8-haloalkoxy, C_1-C_8-alkylthio, $-SO_2$-C_1-C_8-alkyl, C_1-C_8-alkoxycarbonyl, C_1-C_8-acylamino optionally substituted on the nitrogen atom by C_1-C_8-alkyl, C_1-C_8-alkylamino, aminocarbonyl, C_1-C_8-alkylamino-carbonyl, di(C_1-C_8-alkyl)amino, di(C_1-C_8-alkyl)aminocarbonyl, di(C_1-C_8-alkyl)aminocarbonyl-methoxy, or R^2 and R^3 together with the nitrogen atom to which they are attached denote a heterocyclic group having 5 to 10 ring atoms of which 1, 2 or 3 are hetero atoms;
R^4 and R^5 are each independently hydrogen or C_1-C_8-alkyl, or R^4 is hydrogen and R^5 is hydroxy-C_1-C_8-alkyl, acyl, $-SO_2R^8$ or $-CON(R^6)R^7$, or R^4 and R^5 together with the nitrogen atom to which they are attached denote a 5-or 6-membered heterocyclic group;
R^6 and R^7 are each independently hydrogen or C_1-C_8-alkyl, or R^6 and R^7 together with the nitrogen atom to which they are attached denote a 5- or 6-membered heterocyclic group; and
R^8 is C_1-C_8-alkyl, C_1-C_8-haloalkyl, or phenyl optionally substituted by C_1-C_8-alkyl.

Claim 12. (**Currently Amended**) A compound according to claim 11, which is

(i) a compound of formula Ia or its pharmaceutically acceptable salts ~~in free or salt form~~, wherein

Ar is phenyl substituted by halo;

X^1 is -S-, -S(=O)- or $-S(=O)_2$-;

m is 2;

R^1 is C_1-C_8-alkyl optionally substituted by hydroxy or C_1-C_8-alkoxy;

Y is oxygen;

R^2 is hydrogen; and

R^3 is a heterocyclic group having 5 to 11 ring atoms of which 1 to 4 are hetero atoms; or

(ii) a compound of formula Ib or its pharmaceutically acceptable salts ~~in free or salt form~~, wherein

Ar is phenyl substituted by halo;

X^2 is -O-, -C(=O)- or $-CH_2$-;

m is 1 or 2;

Q has the formula



where R^a is C_1-C_8-alkylene,

or Q is $-C(R^b)(R^c)$- where R^b and R^c are independently C_1-C_8-alkyl

or R^b and R^c together form a C_3-C_{10}-cycloalkyl;

R^2 is hydrogen; and

R^3 is a heterocyclic group having 5 to 11 ring atoms of which 1 to 4 are hetero atoms.

Claim 13. (**Currently Amended**) A compound according to claim 11, which is

(i) a compound of formula Ia or its pharmaceutically acceptable salts ~~in free or salt form~~, wherein

Ar is phenyl substituted by halo, preferably chloro;

X^1 is -S-, -S(=O)- or $-S(=O)_2$-;

m is 2;

R^1 is C_1-C_4-alkyl optionally substituted by hydroxy or C_1-C_4-alkoxy;

Y is oxygen;

R^2 is hydrogen; and

R^3 is a heterocyclic group having 5, 6 or 7 ring atoms of which one, two, three or four, are hetero atoms selected from nitrogen, oxygen and sulphur, said heterocyclic group being optionally substituted by C_1-C_4-alky, C_1-C_4-alkoxy or C_3-C_6-cycloalkyl; or

(ii) a compound of formula Ib or its pharmaceutically acceptable salts ~~in free or salt form~~, wherein

Ar is phenyl substituted by halo, preferably chloro;

X^2 is -O-, -C(=O)- or $-CH_2$-;

m is 1 or 2;

Q has the formula

where R^a is C_1-C_8-alkylene,

or Q is $-C(R^b)(R^c)$- where R^b and R^c are independently C_1-C_4-alkyl

or R^b and R^c together form a C_3-C_6-cycloalkyl;

R^2 is hydrogen; and

R^3 is a heterocyclic group having 5, 6 or 7 ring atoms of which one, two, three or four, are hetero atoms selected from nitrogen, oxygen and sulphur, said heterocyclic group being optionally substituted by C_1-C_4-alkyl or C_3-C_6-cycloalkyl.

Claim 14. (**Currently Amended**) A compound according to claim 11 or a pharmaceutically acceptable salt thereof that is selected from the group consisting of:

1-{(S)-3-[3-(4-Chloro-benzenesulfinyl)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(3,5-dimethoxy-phenyl)-urea;

1-{(S)-3-[3-(4-Chloro-benzenesulfinyl)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-[1,3,4]thiadiazol-2)-urea;

1-{(S)-3-[3-(4-Chloro-benzenesulfinyl)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-2-methyl-2H-pyrazol-3-yl)-urea;

1-{(S)-3-[3-(4-Chloro-benzenesulfinyl)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-cyclopropyl-2-methyl-2H-pyrazol-3-yl)-urea;

1-{(S)-3-[3-(4-Chloro-benzenesulfinyl)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-isoxazol-3-yl)-urea;

1-{(S)-3-[3-(4-Chloro-benzenesulfinyl)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(3-ethyl-isoxazol-5-yl)-urea;

1-{(S)-3-[3-(4-Chloro-phenylsulfanyl)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-[1,3,4]thiadiazol-2-yl)-urea;

1-{(S)-3-[3-(4-Chloro-phenylsulfanyl)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-2-methyl-2H-pyrazol-3-yl)-urea;

1-{(S)-3-[3-(4-Chloro-phenylsulfanyl)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-cyclopropyl-2-methyl-2H-pyrazol-3-yl)-urea;

1-{(S)-3-[3-(4-Chloro-phenylsulfanyl)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(3,5-dimethoxy-phenyl)-urea;

1-{(S)-3-[3-(4-Chloro-phenylsulfanyl)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-isoxazol-3-yl)-urea;

1-{(S)-3-[3-(4-Chloro-phenylsulfanyl)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(3-ethyl-isoxazol-5-yl)-urea;

1-{(S)-3-[3-(4-Chloro-benzenesulfonyl)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-[1,3,4]thiadiazol-2-yl)-urea;

1-{(S)-3-[3-(4-Chloro-benzenesulfonyl)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-2-methyl-2H-pyrazol-3-yl)-urea;

1-{(S)-3-[3-(4-Chloro- benzenesulfonyl)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-cyclopropyl-2-methyl-2H-pyrazol-3-yl)-urea;

1-{(S)-3-[3-(4-Chloro- benzenesulfonyl)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(3,5-dimethoxy-phenyl)-urea;

1-{(S)-3-[3-(4-Chloro-benzenesulfonyl)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-isoxazol-3-yl)-urea; and

1-{(S)-3-[3-(4-Chloro-benzene-sulfonyl)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(3-ethyl-isoxazol-5-yl)-urea.

(+/-)-1-{(1R,2R)-2-[3-(4-Chloro-phenoxy)-azetidin-1-yl-methyl]-cyclohexyl}-3-(5-ethyl-[1,3,4]thiadiazol-2-yl)-urea;

1-{(1R,2R)-2-[3-(4-Chloro-phenoxy)-azetidin-1-yl-methyl]-cyclohexyl}-3-(5-ethyl-2-methyl-2H-pyrazol-3-yl)-urea;

1-{(1R,2R)-2-[3-(4-Chloro-phenoxy)-azetidin-1-yl-methyl]-cyclohexyl}-3-(5-cyclopropyl-2-methyl-2H-pyrazol-3-yl)-urea;

1-{(1R,2R)-2-[3-(4-Chloro-phenoxy)-azetidin-1-yl-methyl]-cyclohexyl}-3-(5-cyclobutyl-2-methyl-2H-pyrazol-3-yl)-urea;

1-{(1R,2R)-2-[3-(4-Chloro-phenoxy)-azetidin-1-yl-methyl]-cyclohexyl}-3-(2-ethyl-2H-tetrazol-5-yl)-urea;

1-{(1R,2R)-2-[3-(4-Chloro-phenoxy)-azetidin-1-yl-methyl]-cyclohexyl}-3-(5-ethyl-isoxazol-3-yl)-urea;

1-{(1R,2R)-2-[3-(4-Chloro-phenoxy)-azetidin-1-yl-methyl]-cyclohexyl}-3-(3-ethyl-isoxazol-5-yl)-urea;

1-(1-{2-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-ethyl}-cyclobutyl)-3-(5-ethyl-[1,3,4]thiadiazol-2-yl)-urea;

1-(1-{2-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-ethyl}-cyclobutyl)-3-(5-ethyl-2-methyl-2H-pyrazol-3-yl)-urea;

1-(1-{2-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-ethyl}-cyclobutyl)-3-(5-cyclopropyl-2-methyl-2H-pyrazol-3-yl)-urea;

1-(1-{2-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-ethyl}-cyclobutyl)-3-(5-cyclobutyl-2-methyl-2H-pyrazol-3-yl)-urea;

1-(1-{2-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-ethyl}-cyclobutyl)-3-(2-ethyl-2H-tetrazol-5-yl)-urea;

1-(1-{2-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-ethyl}-cyclobutyl)-3-(5-ethyl-isoxazol-3-yl)-urea;

1-(1-{2-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-ethyl}-cyclobutyl)-3-(3-ethyl-isoxazol-5-yl)-urea;

1-{3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1,1-dimethyl-propyl}-3-(5-ethyl-[1,3,4]thiadiazol-2-yl)-urea;

1-{3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1,1-dimethyl-propyl}-3-(5-ethyl-2-methyl-2H-pyrazol-3-yl)-urea;

1-{3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1,1-dimethyl-propyl}-3-(5-cyclopropyl-2-methyl-2H-pyrazol-3-yl)-urea;

1-{3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1,1-dimethyl-propyl}-3-(5-cyclobutyl-2-methyl-2H-pyrazol-3-yl)-urea;

1-{3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1,1-dimethyl-propyl}-3-(2-ethyl-2H-tetrazol-5-yl)-urea;

1-{3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1,1-dimethyl-propyl}-3-(5-ethyl-isoxazol-3-yl)-urea; and

1-{3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1,1-dimethyl-propyl}-3-(3-ethyl-isoxazol-5-yl)-urea.

Claim 15. (**Currently Amended**) A pharmaceutical composition comprising a compound according to claim 11 or a pharmaceutically acceptable salt thereof in combination with another drug substance ~~which is~~ selected from an anti-inflammatory, a bronchodilator, an antihistamine or an anti-tussive substance.

Claim 16. (**Currently Amended**) A pharmaceutical composition comprising as active ingredient a compound according to claim 11, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

Claim 17. (**Currently Amended**) A pharmaceutical composition comprising as active ingredient a compound according to claim 14, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

Claim 18. (**Withdrawn – Currently Amended**): A method of treating a condition mediated by CCR-3 in a subject in need of such treatment, which comprises administering to said subject an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof ~~as defined in claim 11 in free form or in the form of a pharmaceutically acceptable salt~~.

Claim 19. (**Withdrawn – Currently Amended**): A method of treating an inflammatory or obstructive airways disease in a subject in need of such treatment, which comprises administering to said subject an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof ~~as defined in claim 11 in free form or in the form of a pharmaceutically acceptable salt~~.

Claim 20. (**Withdrawn**): A process for the preparation of a compound of formula Ia or Ib as claimed in claim 11 which comprises

(i) (A) for the preparation of compounds of formula Ia where R^2 is hydrogen, reacting a compound of formula IIa



IIa

or a protected form thereof, where Ar, X^1, m and R^1 are as defined in claim 11, with a compound of formula III



III

where Y and R^3 are as defined in claim 11; or

(B) for the preparation of compounds of formula Ia where Y is oxygen, reacting a compound of formula IIa where Ar, X^1, m and R^1 are as defined in claim 11, with a compound of formula IV



IV

where R^2 and R^3 are as defined in claim 11; or

(C) for the preparation of compounds of formula Ia where X^1 is $-S(=O)_2-$, oxidising a compound of formula Ia in protected form where X^1 is –S- and Ar, m, R^1, Y, R^2 and R^3 are as defined in claim 11;

(D) for the preparation of compounds of formula Ib, reacting a compound of formula IIb



IIb

where Ar, X^2, m and Q are as defined in claim 11, with a compound of formula IV where R^2 and R^3 are as defined in claim 11;

(E) for the preparation of compounds of formula Ib where R^2 is hydrogen, reacting a compound of formula IIb where Ar, X^2, m and Q are as defined in claim 11, with a compound of formula V

V

where R^3 is as defined in claim 11; or

(F) for the preparation of compounds of formula Ib where X is $-S(=O)_2-$, oxidising a compound of formula Ib in protected form where X^2 is -S- and Ar, m, Q, R^2 and R^3 are as defined in claim 11; and

(ii) recovering the product in free or salt form.